Comparative Pharmacology
Head-to-head clinical analysis: PHOSLO versus RENAGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLO versus RENAGEL.
PHOSLO vs RENAGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium acetate binds phosphate in the gastrointestinal tract, forming insoluble calcium phosphate that is excreted in feces, thereby reducing serum phosphate levels.
Sevelamer is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and reducing serum phosphate levels.
667 mg (two 667-mg tablets or one 667-mg capsule) orally three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL; maximum 4000 mg/day.
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 1 tablet/capsule per meal based on serum phosphorus levels. Maintenance: typically 2-4 tablets/capsules per meal.
None Documented
None Documented
Not applicable; minimal systemic absorption, local gastrointestinal action
Not applicable (non-absorbable polymer; systemic absorption <0.01%).
Primarily fecal as unabsorbed drug; minimal renal elimination (<0.5%)
Renal: 0%; Fecal: >99% (as intact drug, due to non-absorbable polymer). Biliary: negligible.
Category C
Category C
Phosphate Binder
Phosphate Binder